Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; iron oxide yellow; purified talc; peg-40 hydrogenated castor oil; methacrylic acid - ethyl acrylate copolymer (1:1); lactose monohydrate; maize starch; triethyl citrate; povidone; hypromellose; titanium dioxide - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: sodium starch glycollate type a; iron oxide yellow; povidone; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; microcrystalline cellulose; titanium dioxide; purified talc; magnesium stearate; hypromellose; lactose monohydrate; triethyl citrate; peg-40 hydrogenated castor oil; colloidal anhydrous silica - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; purified talc; povidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; iron oxide red; hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); triethyl citrate; sodium starch glycollate type a; maize starch; peg-40 hydrogenated castor oil; magnesium stearate; iron oxide yellow - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: peg-40 hydrogenated castor oil; magnesium stearate; purified talc; povidone; sodium starch glycollate type a; hypromellose; titanium dioxide; maize starch; triethyl citrate; iron oxide red; iron oxide yellow; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; methacrylic acid - ethyl acrylate copolymer (1:1) - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - diclofenac sodium; misoprostol - gastro-resistant tablet - 50mg ; 200microgram

United States - English - NLM (National Library of Medicine)

stat rx usa llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 16.05 mg in 1 ml - pennsaid is a nonsteroidal anti-inflammatory drug (nsaid) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). pennsaid is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of pennsaid. pennsaid is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.10) ] . pennsaid is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] . pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. teratogenic effects: there are no adequate and well-controlled studies of pennsaid in pregnant women. pennsaid should not be used by pregnant women as its safe use has not been adequately determined and starting at 30 weeks gestation, diclofen

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - diclofenac sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - diclofenac sodium -